The federally mandated 5-panel drug test required for all DOT-regulated safety-sensitive employees. Screens 5 drug categories covering 14 individual substances — including expanded opioids since January 2018. Collected under strict 49 CFR Part 40 chain-of-custody procedures.
The DOT 5 panel drug test is the federally mandated drug testing standard for safety-sensitive employees under Department of Transportation regulations. Conducted at HHS-certified (SAMHSA-certified) laboratories, it screens urine specimens for five categories of controlled substances. Collected under the strict chain-of-custody procedures required by 49 CFR Part 40, every specimen is analyzed, reviewed by a Medical Review Officer (MRO), and reported under proper regulatory protocol.
As of January 1, 2018, the DOT updated its 5-panel specifications. The former "Opiates" category was renamed "Opioids" and expanded to include four semi-synthetic opioids — hydrocodone, hydromorphone, oxycodone, and oxymorphone. The Amphetamines category was also updated. The result: while the panel count remains at 5, confirmation testing now covers 14 individual substances. Every DOT drug test conducted at Midwest Identity Services follows these current specifications.
Despite the expanded substance list, collectors still check the single "5-panel" box (THC, COC, PCP, OPI, AMP) in Step 1 of the Custody and Control Form (CCF). The expanded opioid confirmatory testing happens at the laboratory level — it does not change the collection procedure or the form used.
The test screens five drug categories. Since January 2018, the panel covers 14 individual substances at the confirmation stage. Here is a complete breakdown of every substance tested.
Tests for the presence of THC metabolites from cannabis use. Under DOT federal regulations, a positive marijuana result cannot be excused by a state medical marijuana card, prescription, or any state law — marijuana remains a Schedule I controlled substance under federal law.
Tests for cocaine and its primary metabolite benzoylecgonine. Cocaine is a Schedule II controlled substance. A positive result on this panel requires immediate removal from safety-sensitive duties pending MRO review.
The 2018 update added initial testing for MDA and removed testing for MDEA from this category. Confirmation testing is conducted when appropriate for all four substances.
Formerly "Opiates," this category was renamed and significantly expanded in January 2018 to include four semi-synthetic opioids. This is the most impactful change in the 2018 DOT update — common prescription painkillers now fall within this panel.
Tests for phencyclidine, commonly known as PCP or "angel dust." PCP is a Schedule II hallucinogenic drug with no accepted medical use in safety-sensitive transportation roles. Confirmation testing is conducted when appropriate.
The 2018 update brought the most significant change to DOT drug testing in many years — expanding the opioids panel to address the opioid crisis and updating the amphetamines category.
The DOT 5 panel drug test is required for any employee in a safety-sensitive position regulated by a DOT operating agency. Here are the primary categories of covered roles.
Both are "5-panel tests" but they are not interchangeable. If your employer requires DOT testing, a non-DOT test result cannot be substituted.
| Feature | DOT 5 Panel | Non-DOT 5 Panel |
|---|---|---|
| Governing Regulation | 49 CFR Part 40 — federal mandate | Employer-defined policy |
| Laboratory Requirement | SAMHSA-certified only | Any certified lab |
| Chain of Custody | Strict federal CCF form required | Standard COC — less rigid |
| MRO Review | Required on all non-negative results | Optional — employer discretion |
| Opioid Sub-Panel | 7 opioids including semi-synthetics | Typically codeine & morphine only |
| Amphetamine Sub-Panel | Amp, Meth, MDMA, MDA | Amp & Meth typically |
| Interchangeable for Compliance | Accepted for all DOT requirements | Cannot substitute for DOT test |
| Result Reporting | MRO reports to employer and Clearinghouse | Lab or employer-defined |
If your role is safety-sensitive under any DOT operating agency (FMCSA, FAA, FRA, FTA, PHMSA), you need DOT testing — and a non-DOT test will not satisfy that requirement. Call us at (816) 442-0295 and we'll confirm which test type applies to your situation in under two minutes.
Every DOT 5 panel test we conduct follows current 49 CFR Part 40 specifications — including the expanded 2018 opioid panel — with proper chain-of-custody and SAMHSA-certified lab analysis.
Our DOT 5 panel tests use the updated specifications effective January 1, 2018 — including the expanded opioids panel covering hydrocodone, oxycodone, hydromorphone, and oxymorphone. You will not receive an outdated test that misses current federal requirements.
Strict federal collection procedures — correct CCF form, proper chain-of-custody documentation, and compliant specimen handling on every test. Procedural errors during collection can invalidate a result entirely.
All DOT specimens go to a SAMHSA-certified (HHS-certified) laboratory — the only type authorized to analyze specimens for federal DOT drug testing. Non-SAMHSA labs are not acceptable for DOT compliance.
All non-negative results are reviewed by a certified Medical Review Officer (MRO) who verifies results, contacts the employee about legitimate medical explanations, and issues the final verified result to the employer.
We support all six DOT-required test circumstances — pre-employment, random, reasonable suspicion, post-accident, return-to-duty, and follow-up. One provider for your complete DOT testing program.
Individual tests and full employer compliance programs — random pool management, FMCSA Clearinghouse query support, and ongoing DOT testing program administration for carriers of any size.
More questions? Call (816) 442-0295 and we'll answer in two minutes.
Current 2018 specifications · SAMHSA-certified lab · MRO-reviewed results · All six DOT test types supported.
8101 E. Bannister Rd · Kansas City, MO 64134 · Cost: $60–$99 based on services needed
